Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer
Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
The concurrent neoadjuvant chemoradiation therapy is standard care for local advanced rectal
cancer (LARC), however, this regimen may induce sorts of adverse events, and part of them
even more severer. A number of pilot studies had shown high rate of complete resection after
neoadjuvant chemotherapy alone, but the results did not increase the ratio of pathological
complete response (pCR), which was associated with overall survival (OS). Here, the
investigators adopt the three active cytotoxic agents (Fluorouracil, Oxaliplatin, Irinotecan,
FOLFOXIRI) as the neoadjuvant chemotherapy regimen to replace the concurrent chemoradiation
and to improve the ratio of pCR further.